Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.

ABSTRACT:

Context

Up to 40% of patients with polycystic ovary syndrome (PCOS) have prediabetes; an optimal pharmacotherapy regimen for diabetes prevention in PCOS is yet to be established.

Objective

To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS.

Design

Randomized, open-label, parallel-group controlled trial.

Setting

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.

Patients

PCOS with prediabetes (fasting plasma glucose 5.6-6.9 mmol/L and/or 2 hour post glucose 7.8-11.0 mmol/L on oral glucose tolerance test [OGTT]). A total of 150 out of 183 eligible enrollees completed the study.

Intervention

EX (10-20μg daily), MET (1500-2000 mg daily), or COM (EX plus MET) for 12

SUBMITTER: Tao T 

PROVIDER: S-EPMC8244122 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature